Back to Search
Start Over
RINVOQ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
- Source :
- Plus Company Updates. February 6, 2020
- Publication Year :
- 2020
-
Abstract
- NORTH CHICAGO: AbbVie has issued the following press release: AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.614476522